Validation of diabetes medication adherence scale in the Lebanese population. 2019

Zahraa Mallah, and Yasmin Hammoud, and Sanaa Awada, and Samar Rachidi, and Salam Zein, and Hajar Ballout, and Amal Al-Hajje
Research Clinical Pharmacy and Pharmaco-epidemiology, Lebanon; Clinical and Epidemiological Research Laboratory, Faculty of Pharmacy, Lebanese University, Campus Hadath, Beirut, Lebanon.

OBJECTIVE To validate the Diabetes Medication Adherence Scale (DMAS-7), determine its concordance with another validated scales and to assess factors affecting medication adherence. METHODS A cross-sectional study was conducted on a sample of Lebanese patients with diabetes using a questionnaire. The level of adherence was measured using the DMAS-7 and the Lebanese Medication Adherence Scale (LMAS-14). Bivariate and multivariate analyses were conducted, and the scale was validated in terms of reliability, predictive ability, and construct validity using SPSS version 19. RESULTS Out of 300 eligible patients, the rate of adherence was 33.7%. Measures of validity showed good reliability (Cronbach alpha = 0.627), and good construct validity with LMAS-14 (Spearman's rho = 0.846; Cohen's kappa = 0.711). DMAS-7 was found to be both correlated with LMAS-14 (ICC average measure = 0.675; p-value <0.001) in addition to possessing a better predictive value. Thus, DMAS-7 showed to have good concordance and increased validity compared to LMAS-14. Having an optimal glycated hemoglobin (HbA1C) (OR = 0.779; p = 0.001) and performing regular physical activity (OR 2.328; p = 0.002) increased medication adherence. CONCLUSIONS The DMAS-7 showed to be reliable and valid instrument superior to LMAS-14 in predicting adherence levels to oral anti-diabetic medications, and thus can be used to achieve better glycemic outcomes.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007861 Lebanon A country located in the Middle East, bordering the Mediterranean Sea, between Israel and Syria. The capital is Beirut. Lebanese Republic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Zahraa Mallah, and Yasmin Hammoud, and Sanaa Awada, and Samar Rachidi, and Salam Zein, and Hajar Ballout, and Amal Al-Hajje
October 2019, The International journal of pharmacy practice,
Zahraa Mallah, and Yasmin Hammoud, and Sanaa Awada, and Samar Rachidi, and Salam Zein, and Hajar Ballout, and Amal Al-Hajje
August 2021, International journal of clinical pharmacy,
Zahraa Mallah, and Yasmin Hammoud, and Sanaa Awada, and Samar Rachidi, and Salam Zein, and Hajar Ballout, and Amal Al-Hajje
January 2018, International journal of hypertension,
Zahraa Mallah, and Yasmin Hammoud, and Sanaa Awada, and Samar Rachidi, and Salam Zein, and Hajar Ballout, and Amal Al-Hajje
February 2014, Current medical research and opinion,
Zahraa Mallah, and Yasmin Hammoud, and Sanaa Awada, and Samar Rachidi, and Salam Zein, and Hajar Ballout, and Amal Al-Hajje
March 2008, Schizophrenia research,
Zahraa Mallah, and Yasmin Hammoud, and Sanaa Awada, and Samar Rachidi, and Salam Zein, and Hajar Ballout, and Amal Al-Hajje
January 2012, PloS one,
Zahraa Mallah, and Yasmin Hammoud, and Sanaa Awada, and Samar Rachidi, and Salam Zein, and Hajar Ballout, and Amal Al-Hajje
September 2016, Journal of epidemiology and global health,
Zahraa Mallah, and Yasmin Hammoud, and Sanaa Awada, and Samar Rachidi, and Salam Zein, and Hajar Ballout, and Amal Al-Hajje
January 2021, Risk management and healthcare policy,
Zahraa Mallah, and Yasmin Hammoud, and Sanaa Awada, and Samar Rachidi, and Salam Zein, and Hajar Ballout, and Amal Al-Hajje
January 2018, Pharmacy practice,
Zahraa Mallah, and Yasmin Hammoud, and Sanaa Awada, and Samar Rachidi, and Salam Zein, and Hajar Ballout, and Amal Al-Hajje
April 2019, Journal of evaluation in clinical practice,
Copied contents to your clipboard!